<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578198</url>
  </required_header>
  <id_info>
    <org_study_id>Truximab+MG4101</org_study_id>
    <nct_id>NCT03578198</nct_id>
  </id_info>
  <brief_title>Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)</brief_title>
  <acronym>MG4101</acronym>
  <official_title>Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent&#xD;
      CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined&#xD;
      therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has&#xD;
      relapsed or refractory to prior chemotherapy or chemo-radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Through treatment completion, an average of 25 weeks</time_frame>
    <description>Investigator-assessed, confirmed objective response by revised response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Through treatment completion, an average of 25 weeks</time_frame>
    <description>Confirmed complete remission by revised response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of initiation until the date of first documented progression, whichever came first, assessed up to 2 years</time_frame>
    <description>PFS as defined by revised response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>OS as defined by revised response criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>CD20-positive Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab + MG4101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Rituximab + MG4101&#xD;
Induction phase:&#xD;
Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase&#xD;
Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab + MG4101</intervention_name>
    <description>Induction phase:&#xD;
Rituximab (Truxima) 375mg/m2 IV Weekly (X4)&#xD;
MG4101 3x107 cells/kg IV Weekly (X4)&#xD;
Maintenance phase&#xD;
Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)&#xD;
MG4101 3x107 cells/kg IV q 4 weeks (X4)</description>
    <arm_group_label>Rituximab + MG4101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed indolent CD20-positive NHLs (iNHLs; follicular lymphoma grade&#xD;
             1-3a, marginal zone B-cell lymphoma, small lymphocytic lymphoma, Waldenstrom&#xD;
             macroglobulinemia)&#xD;
&#xD;
          2. CD20-positive iNHL patients who relapsed or progressed&#xD;
&#xD;
          3. ≥ 19 years&#xD;
&#xD;
          4. ECOG PS 0-2&#xD;
&#xD;
          5. At least one bidimensionally measurable disease (or presence of IgM paraproteinemia ≥&#xD;
             2 x ULN for Waldenstrom macroglobulinemia)&#xD;
&#xD;
          6. Adequate hematologic, renal, and hepatic functions&#xD;
&#xD;
          7. Appropriate methods of contraception during the study&#xD;
&#xD;
          8. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not all of the above inclusion criteria are met.&#xD;
&#xD;
          2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks&#xD;
&#xD;
          3. Corticosteroids &gt; 10mg/day during last 28 days&#xD;
&#xD;
          4. Evidence of CNS involvement by lymphomas&#xD;
&#xD;
          5. Active HBV/HCV infections, known HIV infection&#xD;
&#xD;
          6. Prior diagnosis of cancers within 5 years&#xD;
&#xD;
          7. Serious concurrent cardiovascular disease&#xD;
&#xD;
          8. Patients who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Min Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Tae Min Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

